Look back at pharma news in week to January 25

By Barbara Obstoj-Cardwell

Having been somewhat slow on approving biosimilars, the US Food and Drug Administration last week added clearance to a third version of Roche’s Herceptin, Samsung Bioepis’ Ontruzant. On the research front, Aurinia Pharmaceuticals is pushing ahead with its dry eye therapy candidate voclosporin despite disappointing trial data. Also last week, the UK government set out plans to help control antibiotic resistance, including a new payment model. Additionally, the fourth-quarter 2018 financial results season kicked off, with disappointing figures from AbbVie and mixed ones from Johnson & Johnson.

FDA approves third biosimilar of Roche’s Herceptin